Category: Covid-19 Vaccine

Page 608«..1020..607608609610..620630..»

Fainting and fever – the first side effects of new Covid-19 vaccine trials – AS English

June 28, 2020

Scientists around the world have been working on developing a vaccine to cure the coronavirus since the virus was first detected late last year. By 28 June, there have been almost 10 million confirmed cases around the world with the death toll about to reach 500,000. The United States is the epicenter of the pandemic.

A number of Covid-19 vaccines are currently being trialled in humans, with companies committing to manufacture them on a large scale. The University of Oxford and Imperial College London are two of the multiple research institutes working day and night to produce a vaccine. They hope to have results by the end of the year with secured deals for mass manufacturing.

There are four separate studies which form the main contenders for a coronavirus vaccine, two from China, one in the United States and one in the United Kingdom. Some of these studies have reached the third and final phase of clinical testing.

The vaccine developed by the Vaccine Research Centre of the USA and Modern company has already started human trialswith their vaccine candidate; unfortunately, a 29-year-old volunteer named Ian Haydon suffered a severe reaction to the dose. According to the STAT medical journey, 12 hours after being administered a dose, he developed a high fever of over 39.5 C. His fever was so high that he was admitted to accidents and emergencies where hefainted and passed out.

In the UK, more than 4,000 participants are already enrolled, with enrolment of a further 10,000 people planned as researchers test the vaccine known as ChAdOx1 nCoV-19. The phase one in healthy adult volunteers began in April.

Read more here:

Fainting and fever - the first side effects of new Covid-19 vaccine trials - AS English

Trying to reach herd immunity without a COVID-19 vaccine is a disastrous pandemic response strategy – Milwaukee Independent

June 28, 2020

Since the start of the coronavirus pandemic, use of the term herd immunity has spread almost as fast as the virus. But its use is fraught with misconceptions.

In the U.K., officials briefly considered a herd immunity strategy to protect the most vulnerable members of its population by encouraging others to become exposed and develop immunity to the virus. Others reignited the discussion by focusing on how far we are from herd immunity. But trying to reach herd immunity without a vaccine would be a disastrous pandemic response strategy.

As mathematics and computer science professors, we think it is important to understand what herd immunity actually is, when its a viable strategy and why, without a vaccine, it cannot reduce deaths and illnesses from the current pandemic.

What is herd immunity?

Epidemiologists define the herd immunity threshold for a given virus as the percentage of the population that must be immune to ensure that its introduction will not cause an outbreak. If enough people are immune, an infected person will likely come into contact only with people who are already immune rather than spreading the virus to someone who is susceptible.

Herd immunity is usually discussed in the context of vaccination. For example, if 90% of the population (the herd) has received a chickenpox vaccine, the remaining 10% (often including people who cannot become vaccinated, like babies and the immunocompromised) will be protected from the introduction of a single person with chickenpox.

But herd immunity from SARS-CoV-2 is different in several ways:

1) We do not have a vaccine. As biologist Carl Bergstrom and biostatistician Natalie Dean pointed out in a New York Times op-ed in May, without a widely available vaccine, most of the population 60%-85% by some estimates must become infected to reach herd immunity, and the viruss high mortality rate means millions would die.

2) The virus is not currently contained. If herd immunity is reached during an ongoing pandemic, the high number of infected people will continue to spread the virus and ultimately many more people than the herd immunity threshold will become infected likely over 90% of the population.

3) The people most vulnerable are not evenly spread across the population. Groups that have not been mixing with the herd will remain vulnerable even after the herd immunity threshold is reached.

Reaching herd immunity without a vaccine is costly

For a given virus, any person is either susceptible to being infected, currently infected or immune from being infected. If a vaccine is available, a susceptible person can become immune without ever becoming infected. Without a vaccine, the only route to immunity is through infection. And unlike with chickenpox, many people infected with SARS-CoV-2 die from it.

By mid-June, more than 115,000 people in the U.S. had died from COVID-19, and the disease can have lingering health consequences for those who survive. Moreover, scientists dont yet know the extent to which people who recover are immune from future infections. A vaccine is the only way to move directly from susceptibility to immunity, bypassing the pain from becoming infected and possibly dying.

Herd immunity reached during a pandemic doesnt stop the spread

An ongoing pandemic doesnt stop as soon as the herd immunity threshold is reached. In contrast to the scenario of a single person with chickenpox entering a largely immune population, many people are infected at any given time during an ongoing pandemic.

When the herd immunity threshold is reached during a pandemic, the number of new infections per day will decline, but the substantial infectious population at that point will continue to spread the virus. As Bergstrom and Dean noted, A runaway train doesnt stop the instant the track begins to slope uphill, and a rapidly spreading virus doesnt stop right when herd immunity is attained.

If the virus is unchecked, the final percentage of people infected will far overshoot the herd immunity threshold, affecting as many as 90% of the population in the case of SARS-CoV-2. Proactive mitigation strategies like social distancing and wearing masks flatten the curve by reducing the rate that active infections generate new cases. This delays the point at which herd immunity is reached and also reduces casualties, which should be the goal of any response strategy.

Herd immunity does not protect the vulnerable

People who are particularly vulnerable to COVID-19, such as people over 65, have been urged to stay inside to avoid exposure. However, many of these people live and socialize in communities of people in the same cohort. Even if the herd immunity threshold is reached by the population at large, a single infected person coming in contact with a vulnerable community can cause an outbreak. The coronavirus has devastated nursing homes, which will remain vulnerable until vaccines are available.

How to respond to a pandemic without a vaccine

Without a vaccine, we should not think of herd immunity as a light at the end of the tunnel. Getting there would result in millions of deaths in the United States and would not protect the most vulnerable. For now, washing hands, wearing masks and social distancing remain the best ways to lessen the destruction of COVID-19 by flattening the curve to buy time to develop treatments and vaccines.

More here:

Trying to reach herd immunity without a COVID-19 vaccine is a disastrous pandemic response strategy - Milwaukee Independent

Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients – Pink Sheet

June 26, 2020

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Firefox Add-ons Store.

Go here to see the original:

Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients - Pink Sheet

Help researchers in the search for a COVID-19 vaccine from your home computer – KTVI Fox 2 St. Louis

June 26, 2020

ST. LOUIS You and your home computer could help discover a medicine, vaccine, or even a cure for COVID-19. Its is an amazing story and happening right here in St. Louis.

The more people we get the faster we can go, said Dr. Greg Bowman, a researcher at Washington University School of Medicine.

Bowman and his team are tying together home and work computers from around the world and using all that computing power to help cure COVID-19.

These calculations could easily take 10 million years on a single computer. When you get 10 million computers working together, we can now do them in a year, he said.

So far, they have 4 million computers connected. The computers have created a model created by all those machines which shows the coronavirus attaching to a human cell and infecting it.

The virus is made up of proteins or tiny like machines. Researchers are creating a map of what the proteins can do.

Trying to understand how they work and, in this case, how we can break them to prevent the virus from infecting us and taking over our cells and replicating itself, Bowman said.

Those millions of computers do all the work. Your computer can too. You download a program and, while you sleep, your computer goes to work and youve become a citizen scientist.

Bowman said theres lots of security built into the program to keep your computer from becoming infected. Researchers have promising results they hope to publish in the soon.

Our estimate we are 5 to 10 times more powerful than the worlds fastest super computer, he said.

After COVID-19 is solved, researchers will return to working on Alzheimers and Ebola.(web editors please include the following after my story thanks roche)

To download the Folding@home software and start contributing to COVID-19 research, visit https://foldingathome.org/start-folding/.

View post:

Help researchers in the search for a COVID-19 vaccine from your home computer - KTVI Fox 2 St. Louis

Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of ‘Operation Warp Speed’ – MarketWatch

June 26, 2020

Vaxart Inc. VXRT, +71.88% said Friday its oral COVID-19 vaccine has been selected to take part in a non-human primate challenge study funded by the U.S. government's 'Operation Warp Speed' program, that aims to accelerate development of a vaccine. The study is designed to evaluate the efficacy of the candidate. Chief Executive Andrei Floroiu said it's the only oral candidate in the program. "SARS-CoV-2, the coronavirus that causes COVID-19, is primarily transmitted by viral particles that enter through the mucosa - nose, mouth or eyes - strongly suggesting that mucosal immunity could serve as the first line of defense," he said in a statement. "In addition, our vaccine is a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns." Vaxart shares soared 75% premarket on the news. The stock has skyrocketed since the start of the year and is up more than 1,600%.

Read more here:

Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed' - MarketWatch

BRIEF-VaxartS Covid-19 Vaccine Selected For The U.S. GovernmentS Operation Warp Speed – Reuters

June 26, 2020

June 26 (Reuters) - Vaxart Inc:

* VAXARTS COVID-19 VACCINE SELECTED FOR THE U.S. GOVERNMENTS OPERATION WARP SPEED

* VAXART - COS ORAL COVID-19 VACCINE SELECTED TO PARTICIPATE IN A NON-HUMAN PRIMATE CHALLENGE STUDY ORGANIZED & FUNDED BY OPERATION WARP SPEED Source text for Eikon: Further company coverage:

See the original post here:

BRIEF-VaxartS Covid-19 Vaccine Selected For The U.S. GovernmentS Operation Warp Speed - Reuters

Sanofi CEO on two-pronged approach to developing Covid-19 vaccine – CNBC

June 24, 2020

Investors are watching the race to develop a coronavirus vaccine closely for signs of when the U.S. economy can begin to get back on track. Sanofi is one of the drugmakers leading the charge with clinical trials, which are expected to start later this year. Sanofi CEO Paul Hudson joins "Squawk Box" to discuss the latest regarding vaccine developments.

05:50

Tue, Jun 23 20208:04 AM EST

See the article here:

Sanofi CEO on two-pronged approach to developing Covid-19 vaccine - CNBC

Page 608«..1020..607608609610..620630..»